Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.47 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30849680 | 0.91 | CYP19A1 (0.45) | HTR2AHTR2CHTR7AOC3CYP19A1 | |
| SCHEMBL30849687 | 0.90 | KDM4E (0.51) | HTR2ACYP19A1GRIN2BKDM4E | |
| SCHEMBL5362414 | 0.90 | KDM4E (0.51) | HTR2ACYP19A1GRIN2BKDM4E | |
| SCHEMBL8109000 | 0.87 | CYP19A1 (0.54) | HTR2AHTR2CHTR7AOC3CYP19A1 | |
| SCHEMBL10911201 | 0.81 | CYP19A1 (0.54) | HTR2AHTR2CHTR7CYP19A1MEN1 | |
| SCHEMBL2964767 | 0.81 | ADRB2 (0.62) | TAAR1ADRB2ALOX15TSHRNFKB1 | |
| SCHEMBL14327418 | 0.80 | TAAR1 (0.50) | AOC3TAAR1 | |
| SCHEMBL10397242 | 0.80 | AOC3 (0.52) | HTR2AHTR2CHTR7AOC3GMNN | |
| SCHEMBL8898411 | 0.80 | CA12 (0.43) | — | |
| SCHEMBL11119802 | 0.79 | AOC3 (0.47) | AOC3TAAR1ADRB2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5846966-A | Ezetimibe in combination with statins | SCHERING CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| US-20190169342-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | RELYPSA, INC. (US) | 2019-04-30 | — | — | US | disclosed |
| EP-3130343-B1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2018-05-09 | — | — | EP | disclosed |
| EP-2539389-B1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9655920-B2 | Amine polymers for use as bile acid sequestrants | RELYPSA, INC. (US) | 2017-05-23 | — | — | US | disclosed |
| EP-3130343-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2017-02-15 | — | — | EP | disclosed |
| EP-2538947-B1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2998329-A2 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | Relypsa, Inc. (US) | 2016-03-23 | — | — | EP | disclosed |
| EP-2539380-B1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA INC (US) | 2015-08-19 | — | — | EP | disclosed |
| US-20140356316-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130022570-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | RELYPSA, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8258125-B2 | pharmaceutical composition including therapeutically effective amounts of at least one HMG-CoA reductase inhibitor present as a dyhydroxyacid salt and at least one additional therapeutic agent | TUNAC JOSEFINO B (US) | 2012-09-04 | — | — | US | disclosed |
| US-20080248070-A1 | HDL-Boosting Combination Therapy Complexes | TUNAC JOSEFINO B | 2008-10-09 | — | — | US | disclosed |
| US-7390504-B2 | HDL-boosting combination therapy complexes | JJ PHARMA, INC. (US) | 2008-06-24 | — | — | US | disclosed |
| US-20050101561-A1 | HDL-boosting combination therapy complexes | JJ PHARMA, INC. | 2005-05-12 | — | — | US | disclosed |
| US-5846966-A | Ezetimibe in combination with statins | SCHERING CORPORATION (US) | 1998-12-08 | — | — | US | disclosed |
| US-5767115-A | ADMINISTERING TO PREVENT ATHERSCLEROSIS OR REDUCING PLASMA CHOLESTEROL LEVELS TO THE MAMMALS; INCLUDES EZETIMIBE | SCHERING-PLOUGH CORPORATION (US) | 1998-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258825-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | HTR2A 1133/4885HTR2C 1549/4885HTR7 546/4885 |
| US-20140356316-A1 | AMINE POLYMERS FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, SLC10A1 | HTR2A 1133/4885HTR2C 1549/4885HTR7 546/4885 |
| US-10272103-B2 | Crosslinked polyvinylamine, polyallylamine, and polyethyleneimine for use as bile acid sequestrants | NR1H4, SLC10A2, GPBAR1 | HTR2A 2175/4885HTR2C 2677/4885HTR7 1449/4885 |
| US-20050101561-A1 | HDL-boosting combination therapy complexes | APOB, LDLR, HDLBP | HTR2A 3401/4885HTR2C 3808/4885HTR7 2800/4885 |
| US-20130189215-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, ITCH | HTR2A 2349/4885HTR2C 2010/4885HTR7 1068/4885 |
| US-20190169342-A1 | POLYIMIDAZOLES FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, ITCH | HTR2A 2349/4885HTR2C 2010/4885HTR7 1068/4885 |
| US-20080248070-A1 | HDL-Boosting Combination Therapy Complexes | LDLR, HMGCR, APOB | HTR2A 2893/4885HTR2C 3143/4885HTR7 2073/4885 |
| US-20130022570-A1 | CROSSLINKED POLYVINYLAMINE, POLYALLYLAMINE, AND POLYETHYLENEIMINE FOR USE AS BILE ACID SEQUESTRANTS | NR1H4, SLC10A2, GPBAR1 | HTR2A 2175/4885HTR2C 2677/4885HTR7 1449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.